Cardiovascular Drug–Drug Interactions (DDIs) in Coronary Heart Disease Patients with Hypertension
Article Sidebar
Main Article Content
Page: 2711-2720
Abstract
Coronary heart disease (CHD) accompanied by hypertension often necessitates the use of multiple cardiovascular agents. The concurrent use of multiple drugs increases the risk of drug-drug interactions (DDIs), which may alter drug metabolism, reduce therapeutic efficacy, or cause adverse effects. This study aimed to characterize the potential, mechanisms, and severity of drug interactions; to assess differences in the average number of drugs used per day in relation to the potential for drug interactions; and to assess the clinical profile based on DDI severity levels. A retrospective, analytic, observational method was applied, utilizing secondary data from hospital medical records. Statistical analysis included the Mann–Whitney test to compare the mean number of drugs per day between the interaction potential groups. A total of 52 patients met the inclusion criteria through purposive sampling. The results showed that most CHD patients with a history of hypertension were male (75%) and aged 18–64 years (73.1%). A total of 405 potential DDIs were identified. From these, 80 unique drug-pair interactions were selected for detailed analysis of their mechanisms and severity. Most were pharmacodynamic (77.5%), with aspirin–nitroglycerin the most frequent (7.6%). Among the 80 interactions analyzed in detail, those with moderate severity predominated (58.8%), followed by minor (35%) and major (6.2%). Polypharmacy (defined as the use of three or more medications) was observed in all patients who experienced DDIs. There was a significant difference in the average number of medications per day between patients with potential drug interactions and those without, p = 0.023 (p < 0.05).
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
Dipiro JT, Yee GC, Haines ST, Nolin TD, Ellingrod VL, Posey LM. Pharmacoterapy A Phatophysiologic Approach. 12th ed. 2023.
Shimizu Y. Hypertension WHO 2023. https://www.who.int/news-room/fact-sheets/detail/hypertension.
Kemenkes. Laporan Riskesdas 2018 Nasional (2018 National Riskesdas Report). Lemb Penerbit Balitbangkes 2018:hal 156.
Mattingly Q. Cardiovascular WHO 2024. https://www.who.int/health-topics/cardiovascular-diseases.
Kemenkes. Laporan Riskesdas 2013 Nasional (2013 National Riskesdas Report) 2013. https://doi.org/10.1126/science.127.3309.1275. DOI: https://doi.org/10.1126/science.127.3309.1275
Permatasari D, Husna NA, Yosmar R. Potensial Drug-Drug Interaction of Cardiovascular Drugs Based on Literature in Geriatric Patients with Congestive Heart Failure at Dr. M. Djamil Padang Hospital. Int J Appl Pharm 2024;16:28–34. https://doi.org/10.22159/ijap.2024.v16s1.06. DOI: https://doi.org/10.22159/ijap.2024.v16s1.06
Maulia AN, Kumala MT, Rochmah NN. Kajian Potensi Interaksi Obat Pada Pasien Hipertensi Di Instalasi Rawat Jalan Rumah Sakit X Periode Agustus 2019 (Study of Potential Drug Interactions in Hypertensive Patients in the Outpatient Unit of Hospital X, August 2019). J Ilm JOPHUS J Pharm UMUS 2022;3:111–9. https://doi.org/10.46772/jophus.v3i02.506. DOI: https://doi.org/10.46772/jophus.v3i02.506
Aisyah S, Andini MD, Saputra GH. Overview of Drug Interactions in Geriatric Heart Failure Patients with BPJS Insurance at the Heart Clinic of Jakarta Islamic Hospital Cempaka Putih for the Period October-December 2018. J Farm IKIFA 2021;1:74–80.
Adondis J, Mongi J, Tiwow GAR, Palandi RR. Studi Potensi Interaksi Obat Pada Pasien Gagal Jantung Di Instalasi Rawat Inap Rumah Sakit Advent Manado (Study of Potential Drug Interactions in Heart Failure Patients at the Inpatient Unit of Manado Adventist Hospital). Biofarmasetikal Trop 2019;2:124–35. https://doi.org/10.55724/jbiofartrop.v2i2.125. DOI: https://doi.org/10.55724/jbiofartrop.v2i2.125
Novriyanti ID, Usnizar F, Irwan. The Effect of Duration of Hypertension on Coronary Heart Disease in the Cardiology Clinic of Dr. Mohammad Hoesin General Hospital Palembang 2012. J Kedokt Dan Kesehat 2014;1:55–60. https://doi.org/10.1002/em.20332. DOI: https://doi.org/10.1002/em.20332
Nurhikmawati, Afiifah I, Syahruddin FI, Aspar A, Lestari I. Karakteristik Pasien Hipertensi dengan Gangguan Kardiovaskular (Characteristics of Hypertensive Patients with Cardiovascular Disorders). Fakumi Med J J Mhs Kedokt 2024;4:513–20. https://doi.org/10.33096/fmj.v4i7.479. DOI: https://doi.org/10.33096/fmj.v4i7.479
Shoufiah R. Hubungan Faktor Resiko Dan Karakteristik Penderita Dengan Kejadian Penyakit Jantung Koroner (The Relationship Between Risk Factors and Patient Characteristics and the Incidence of Coronary Heart Disease). Mahakam Nurs J 2016;1:17–26.
PERKI. Pedoman Tata Laksana Sindrom Koroner Akut 2024 (Acute Coronary Syndrome Management Guidelines 2024). vol. 5. 2024.
Mekaj YH, Daci FT, Mekaj AY. New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolism. Ther Clin Risk Manag 2015;11:1449–56. https://doi.org/10.2147/TCRM.S92222. DOI: https://doi.org/10.2147/TCRM.S92222
PERKI. Pedoman Tatalaksana Hipertensi Pada Penyakit Kardiovaskular (Guidelines for the Management of Hypertension in Cardiovascular Disease). Perhimpunan Dokter Spesialis Kardiovaskular Indonesia; 2015.
Tampubolon LF, Ginting A, Turnip FES. Gambaran Faktor yang Mempengaruhi Kejadian Penyakit Jantung Koroner (PJK) di Pusat Jantung Terpadu (PJT) (Overview of Factors Influencing the Incidence of Coronary Heart Disease (CHD) at the Integrated Heart Center (IHC)) 2023;13:1043–52. DOI: https://doi.org/10.32583/pskm.v13i3.1077
Atika Y. Gambaran Faktor Risiko Kejadian Penyakit Jantung Koroner di Poliklinik Jantung RSI Siti Rahmah Padang Tahun 2017-2018 (Overview of Risk Factors for Coronary Heart Disease Events at the Heart Polyclinic of RSI Siti Rahmah Padang in 2017-2018) 2019:20–8. DOI: https://doi.org/10.33854/heme.v3i1.352
Setyoningsih H, Zaini F. Hubungan Interaksi Obat Terhadap Efektivitas Obat Antihipertensi di RSUD dr. R. Soetrasno Rembang (The Relationship between Drug Interactions and the Effectiveness of Antihypertensive Drugs at Dr. R. Soetrasno Regional General Hospital, Rembang). Cendekia J Pharm 2022;6:76–88. https://doi.org/10.31596/cjp.v6i1.186. DOI: https://doi.org/10.31596/cjp.v6i1.186
Azizah LN, Anwar T, Nastiti AD, Muhalla HI, Zuhroidah I, Dwipayanti PI, et al. Buku Ajar Farmakologi Keperawatan (Nursing Pharmacology Textbook). PT. Sonpedia Publishing Indonesia; 2024.
Nuryati. Farmakologi (Pharmacology). Kementerian Kesehatan RI; 2017.
Drugs.com 2025. https://www.drugs.com/drug_interactions.html.
Tatro, David. Drug Interaction Facts. United State of America: Wolters Kluwer Health; 2009.
Drugbank. Drug Interaction Checker 2025. https://go.drugbank.com/drug-interaction-%0Achecker.
Mashar HM, Ilyas M, Mulki MA, Haryani R, Angganawati RT, Ismail. Interaksi Obat (Drug Interactions). Eureka Media Aksara; 2023.
Oktaviani I, Setiadi F, Oktovina MN. Potensi Interaksi Obat Pada Pasien Penyakit Jantung Koroner Akut Di Rawat Inap Rumah Sakit Fatmawati Tahun 2023 (Potential Drug Interactions in Patients with Acute Coronary Heart Disease Hospitalized at Fatmawati Hospital in 2023). J Farm Klin Base Pract 2024;3:56–70. https://doi.org/10.58815/jfklin.v3i2.54. DOI: https://doi.org/10.58815/jfklin.v3i2.54
Baxter K. Stockley’s Drug Interactions. 9th ed. Pharmaceutical Press; 2010.
Dasopang ES, Harahap U, Lindarto D. Polifarmasi dan Interaksi Obat Pasien Usia Lanjut Rawat Jalan dengan Penyakit Metabolik (Polypharmacy and Drug Interactions in Elderly Outpatients with Metabolic Diseases). J Farm Klin Indones 2015;4:235–41. https://doi.org/10.15416/ijcp.2015.4.4.235. DOI: https://doi.org/10.15416/ijcp.2015.4.4.235
Saputri M, Dewi SR. Potensi Interaksi Polifarmasi Pasien Jantung Koroner (PJK) di Rumah Sakit I.A. Moeis Samarinda (Potential Polypharmacy Interactions in Coronary Heart Disease (CHD) Patients at I.A. Moeis Hospital, Samarinda). J Sains Dan Kesehat 2023;5:109–14. https://doi.org/10.25026/jsk.v5i2.1709. DOI: https://doi.org/10.25026/jsk.v5i2.1709
Harahap NRA, Putri RA. The Relationship Between Polypharmacy and Potential Drug-Drug Interactions (DDIs) in Coronary Heart Disease (CHD) Patients at a Private Hospital in Bekasi. J Ris Kefarmasian Indones 2025;7:231–44. DOI: https://doi.org/10.33759/jrki.v7i2.627
Abet MA, Gayatri A. Potensi Interaksi Obat Tersering pada Pasien Sakit Kritis (Potential Most Frequent Drug Interactions in Critically Ill Patients). J Indones Med Assoc 2023;73:206–12. https://doi.org/10.47830/jinma-vol.73.4-2023-1036. DOI: https://doi.org/10.47830/jinma-vol.73.4-2023-1036